Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxiracetam is a synthetic nootropic drug belonging to the racetam family, chemically derived from piracetam. It is recognized for its cognitive-enhancing properties, including improvements in memory, learning, and overall cognitive function. While its precise mechanism of action is still under research, it is believed to modulate both cholinergic and glutamatergic systems in the brain. Oxiracetam enhances the release and synthesis of acetylcholine, a neurotransmitter crucial for learning and memory, and interacts with glutamate receptors, particularly AMPA receptors, to facilitate synaptic transmission and plasticity. It also exhibits neuroprotective properties, influences brain energy metabolism by increasing ATP synthesis, and may increase levels of D-aspartic acid. Oxiracetam is not approved by the U.S. Food and Drug Administration for any medical use in the United States but is widely used as a dietary supplement and is being investigated for various cognitive impairments. Its (S)-enantiomer, L-oxiracetam, is considered the active ingredient and is also under clinical investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oxiracetam.